Guidelines on Muscle-invasive and Metastatic Bladder Cancer

[1]  B. Malavaud,et al.  Complications for radical cystectomy. Impact of the American Society of Anesthesiologists score. , 2001, European urology.

[2]  W. Whitmore,et al.  Randomized trial of cystectomy with or without preoperative radiotherapy for carcinoma of the bilharzial bladder. , 1985, The Journal of urology.

[3]  M. Buglione,et al.  Radical radiotherapy for bladder cancer: retrospective analysis of a series of 459 patients treated in an Italian institution. , 2006, Clinical oncology (Royal College of Radiologists (Great Britain)).

[4]  V. Serretta,et al.  TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years. , 2004, European urology.

[5]  A. Zlotta.  Limited, extended, superextended, megaextended pelvic lymph node dissection at the time of radical cystectomy: what should we perform? , 2012, European urology.

[6]  M. Resnick,et al.  Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. , 2000, The Journal of urology.

[7]  E. Klein,et al.  Lack of pathologic down‐staging with neoadjuvant chemotherapy for muscle‐invasive urothelial carcinoma of the bladder , 2009, Cancer.

[8]  M. Soloway,et al.  Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. , 2008, The Journal of urology.

[9]  T. Kälble,et al.  Metabolic and functional consequences of urinary reconstruction with bowel , 2003, BJU international.

[10]  R. Millikan,et al.  Clinical Cancer esearch cer Therapy : Clinical Effectiveness of Off-Protocol Adjuvant Chemotherapy for R ients with Urothelial Carcinoma of the Urinary Bladder , 2010 .

[11]  S. Groshen,et al.  Radical cystectomy in the elderly , 2005, Cancer.

[12]  Joshua R. Ehrlich,et al.  A comparison of postoperative complications in open versus robotic cystectomy. , 2010, European urology.

[13]  T. Morgan,et al.  Anatomic basis for lymph node counts as measure of lymph node dissection extent: a cadaveric study. , 2013, Urology.

[14]  U. Nagele,et al.  The rationale for radical cystectomy as primary therapy for T4 bladder cancer , 2007, World Journal of Urology.

[15]  J. Cordonnier.  Urinary diversion. , 1957, Transactions of the American Association of Genito-Urinary Surgeons.

[16]  S. Johansson,et al.  A prospective randomized study of preoperative irradiation with cystectomy or cystectomy alone for invasive bladder carcinoma. , 1983, European urology.

[17]  G. Lyman,et al.  Comorbidity and functional status are independent in older cancer patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Wahlqvist,et al.  Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. , 2012, European urology.

[19]  D. Byar,et al.  Results of a clinical trial of surgery and radiation in stages II and 3 carcinoma of the bladder. , 1972, The Journal of urology.

[20]  H. Miyake,et al.  Health-related quality of life after radical cystectomy for bladder cancer: a comparison of ileal conduit and orthotopic bladder replacement , 2002 .

[21]  I. Bross,et al.  Five‐year follow‐up results of a collaborative study of therapies for carcinoma of the bladder , 1977, Journal of surgical oncology.

[22]  Huan-yi Lin,et al.  Comparison of surgical stress response to laparoscopic and open radical cystectomy , 2010, World Journal of Urology.

[23]  S. Fosså,et al.  Neoadjuvant chemotherapy in bladder cancer: a randomized study. Nordic Cystectomy Trial I. , 1993, Scandinavian journal of urology and nephrology.

[24]  M. Milowsky,et al.  Detection of circulating tumor cells in patients with urothelial cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  H. Miyake,et al.  Upper urinary tract recurrence following radical cystectomy for bladder cancer , 2007, International journal of urology : official journal of the Japanese Urological Association.

[26]  J. Stein,et al.  Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure , 2006, World Journal of Urology.

[27]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[28]  C. Rödel,et al.  Organ preservation by combined modality treatment in bladder cancer: the European perspective. , 2005, Seminars in radiation oncology.

[29]  T. Wilt,et al.  Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. , 2015, The Cochrane database of systematic reviews.

[30]  U. Egle,et al.  Quality of life in patients with bladder carcinoma after cystectomy: First results of a prospective study , 2000, Quality of Life Research.

[31]  P. Carroll,et al.  Update on chemotherapy for advanced bladder cancer. , 2005, The Journal of urology.

[32]  C. Morash,et al.  Surveillance strategies after definitive therapy of invasive bladder cancer. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[33]  J. Gore,et al.  Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer , 2013, Advances in urology.

[34]  S. Ricci,et al.  Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer , 2005 .

[35]  D. Lubeck,et al.  Quantifying comorbidity in a disease-specific cohort: adaptation of the total illness burden index to prostate cancer. , 1999, Urology.

[36]  C. Stief,et al.  Predicting individual outcomes after radical cystectomy: an external validation of current nomograms , 2010, BJU international.

[37]  M. Schrader,et al.  The ileal neobladder in female patients with bladder cancer: long-term clinical, functional, and oncological outcome , 2012, World Journal of Urology.

[38]  M. Milowsky,et al.  Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. , 2009, European urology.

[39]  H. von der Maase,et al.  Radical radiotherapy for urinary bladder cancer: treatment outcomes , 2006, Expert review of anticancer therapy.

[40]  A. Younis,et al.  A prospective randomized trial for postoperative vs. preoperative adjuvant radiotherapy for muscle-invasive bladder cancer. , 2013, Urologic oncology.

[41]  S. Hung,et al.  Multidetector computerized tomography urography is more accurate than excretory urography for diagnosing transitional cell carcinoma of the upper urinary tract in adults with hematuria. , 2010, The Journal of urology.

[42]  M. Fortin,et al.  Cumulative Illness Rating Scale was a reliable and valid index in a family practice context. , 2005, Journal of clinical epidemiology.

[43]  M. Dimopoulos,et al.  Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  P. Bendahl,et al.  Extended lymph node dissection in patients with urothelial cell carcinoma of the bladder: can it make a difference? , 2009, World Journal of Urology.

[45]  J. Witjes,et al.  Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional TI-weighted magnetization-prepared-rapid gradient-echo sequence. , 1996, AJR. American journal of roentgenology.

[46]  E. Wallen,et al.  Robotic-assisted laparoscopic intracorporeal urinary diversion. , 2010, European urology.

[47]  S. Fosså,et al.  Clinical significance of routine pre-cystectomy bone scans in patients with muscle-invasive bladder cancer. , 1996, British journal of urology.

[48]  D. Lubeck,et al.  Assessment of prognosis with the total illness burden index for prostate cancer , 2007, Cancer.

[49]  E. Barret,et al.  Robot-assisted laparoscopic cystoprostatectomy with extended pelvic lymphadenectomy, extracorporeal enterocystoplasty, and intracorporeal enterourethral anastomosis: initial Montsouris experience. , 2010, Journal of endourology.

[50]  H. Grossman,et al.  A stage specific approach to tumor surveillance after radical cystectomy for transitional cell carcinoma of the bladder. , 1999, The Journal of urology.

[51]  T. Wilt,et al.  Surgery versus radiotherapy for muscle invasive bladder cancer? , 2001, Clinical oncology (Royal College of Radiologists (Great Britain)).

[52]  M. Kuczyk,et al.  The value of bladder-conserving strategies in muscle-invasive bladder carcinoma compared with radical surgery , 2007, Current opinion in urology.

[53]  Christopher J Kane,et al.  Prospective comparison of computerized tomography and excretory urography in the initial evaluation of asymptomatic microhematuria. , 2002, The Journal of urology.

[54]  A. Prando.  Split-bolus MDCT urography: upper tract opacification and performance for upper tract tumors in patients with hematuria , 2010 .

[55]  J. Au,et al.  Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[56]  E. Messing,et al.  Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. , 2005, Urology.

[57]  Y. Yamada,et al.  Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer. , 2012, International journal of radiation oncology, biology, physics.

[58]  V. Guillem,et al.  Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  Richard H. Cohan,et al.  CT urography: definition, indications and techniques. A guideline for clinical practice , 2007, European Radiology.

[60]  M. May,et al.  Results from three municipal hospitals regarding radical cystectomy on elderly patients. , 2007, International braz j urol : official journal of the Brazilian Society of Urology.

[61]  A. Sagalowsky,et al.  The diagnosis and treatment of urethral recurrence after radical cystectomy. , 2006, Urologic oncology.

[62]  L. Kiemeney,et al.  Epidemiology and risk factors of urothelial bladder cancer. , 2013, European urology.

[63]  Ji-An Liang,et al.  Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis. , 2012, European journal of radiology.

[64]  H. Grossman,et al.  Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. , 2010, The Journal of urology.

[65]  R. Sylvester,et al.  Intravesical BCG in Patients with Carcinoma in situ of the Urinary Bladder: Long–Term Results of EORTC GU Group Phase II Protocol 30861 , 2001, European Urology.

[66]  P. Rochon,et al.  Comorbid illness is associated with survival and length of hospital stay in patients with chronic disability. A prospective comparison of three comorbidity indices. , 1996, Medical care.

[67]  S. Schoenberg,et al.  Whole-body MR imaging of bone marrow. , 2005, European journal of radiology.

[68]  P. Russo,et al.  A role for neoadjuvant gemcitabine plus cisplatin in muscle‐invasive urothelial carcinoma of the bladder , 2008, Cancer.

[69]  P. Malmström,et al.  Impact of hospital volume on local recurrence and distant metastasis in bladder cancer patients treated with radical cystectomy in Sweden , 2013, Scandinavian journal of urology.

[70]  M P Lawton,et al.  Validation of the Cumulative Illness Rating Scale in a Geriatric Residential Population , 1995, Journal of the American Geriatrics Society.

[71]  A. Stenzl,et al.  Incidental prostate cancer at radical cystoprostatectomy: implications for apex‐sparing surgery , 2010, BJU international.

[72]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[73]  J. Witjes,et al.  EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. , 2014, European urology.

[74]  H. Hricak,et al.  Prospective evaluation of MRI, ¹¹C-acetate PET/CT and contrast-enhanced CT for staging of bladder cancer. , 2012, European journal of radiology.

[75]  F. Algaba,et al.  Transitional cell carcinoma of the prostate. , 1985, European urology.

[76]  S. Pahernik,et al.  Long-term followup of the intussuscepted ileal nipple and the in situ, submucosally embedded appendix as continence mechanisms of continent urinary diversion with the cutaneous ileocecal pouch (Mainz pouch I). , 2006, The Journal of urology.

[77]  G. Sonpavde,et al.  Neoadjuvant Chemotherapy for Invasive Bladder Cancer , 2012, Current Urology Reports.

[78]  F. Saad,et al.  Exploration of health-related quality of life areas that may distinguish between continent diversion and ileal conduit patients. , 2005, The Canadian journal of urology.

[79]  R. Hautmann,et al.  Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. , 2005, The Journal of urology.

[80]  W. Otto,et al.  Predictive capacity of four comorbidity indices estimating perioperative mortality after radical cystectomy for urothelial carcinoma of the bladder , 2012, BJU international.

[81]  Sten Nilsson,et al.  Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. , 2004, European urology.

[82]  J. Phillips,et al.  The role of perioperative chemotherapy in the treatment of urothelial cancer. , 2006, The oncologist.

[83]  B. Herts,et al.  The role of computerized tomographic urography in the initial evaluation of hematuria. , 2007, The Journal of urology.

[84]  F. Montorsi,et al.  Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. , 2013, Cancer epidemiology.

[85]  M. Peyromaure,et al.  The value of a second transurethral resection in evaluating patients with bladder tumours. , 2003, European urology.

[86]  R. C. Coffey.  PHYSIOLOGIC IMPLANTATION OF THE SEVERED URETER OR COMMON BILE-DUCT INTO THE INTESTINE , 1911 .

[87]  S. Ramsey,et al.  Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. , 2011, Urologic oncology.

[88]  T. Martini,et al.  Comparison of complications in three incontinent urinary diversions. , 2008, European urology.

[89]  D. Gillatt,et al.  A DELAY IN RADICAL CYSTECTOMY OF >3 MONTHS IS NOT ASSOCIATED WITH A WORSE CLINICAL OUTCOME , 2008, BJU international.

[90]  J. Witjes,et al.  Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. , 2011, European urology.

[91]  M. Stöckle,et al.  Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. , 1995, The Journal of urology.

[92]  W. De Neve,et al.  Radiotherapy for T2 and T3 carcinoma of the bladder: the influence of overall treatment time. , 1995, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[93]  G. Dalbagni,et al.  Defining bacillus Calmette-Guerin refractory superficial bladder tumors. , 2003, The Journal of urology.

[94]  N. Shinohara,et al.  Impact of multimodal treatment on survival in patients with metastatic urothelial cancer. , 2007, European urology.

[95]  T. Kessler,et al.  Do patients benefit from routine follow-up to detect recurrences after radical cystectomy and ileal orthotopic bladder substitution? , 2010, European urology.

[96]  S. Culine,et al.  Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  H. Kumon,et al.  Could salvage surgery after chemotherapy have clinical impact on cancer survival of patients with metastatic urothelial carcinoma? , 2013, International Journal of Clinical Oncology.

[98]  W. Kassouf,et al.  First- and second-line therapy for metastatic urothelial carcinoma of the bladder. , 2011, Current oncology.

[99]  R. Hohenfellner,et al.  Colon pouch (Mainz pouch III) for continent urinary diversion after pelvic irradiation. , 2000, Urology.

[100]  R. Hautmann,et al.  Does the option of the ileal neobladder stimulate patient and physician decision toward earlier cystectomy? , 1998, The Journal of urology.

[101]  B. I. Choi,et al.  Uterine cervical carcinoma: comparison of CT and MR findings. , 1990, Radiology.

[102]  J. Stein,et al.  Results with radical cystectomy for treating bladder cancer: a ‘reference standard’ for high‐grade, invasive bladder cancer , 2003, BJU international.

[103]  J. Witjes,et al.  The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review. , 2014, European urology.

[104]  R. Sylvester,et al.  The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[105]  P. Bassi,et al.  Quality of life after radical cystectomy and orthotopic bladder substitution: a comparison between Italian and Swedish men , 2000, BJU international.

[106]  J. Damber,et al.  A Systematic Overview of Radiation Therapy Effects in Urinary Bladder Cancer , 2003, Acta oncologica.

[107]  J. Chang-Claude,et al.  Cigarette smoking and bladder cancer in men: A pooled analysis of 11 case‐control studies , 2000, International journal of cancer.

[108]  P. Lawler,et al.  An assessment of the consistency of ASA physical status classification allocation , 1995, Anaesthesia.

[109]  S. Boyd,et al.  Radical cystectomy for elderly patients with bladder carcinoma , 1998, Cancer.

[110]  B. I. Choi,et al.  Uterine cervical carcinoma: evaluation of pelvic lymph node metastasis with MR imaging. , 1994, Radiology.

[111]  H. G. van der Poel,et al.  Short-Term Outcome after Cystectomy: Comparison of Two Different Perioperative Protocols , 2012, Urologia Internationalis.

[112]  C. Logothetis,et al.  Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  A. Tizzani,et al.  Morbidity and quality of life in elderly patients receiving ileal conduit or orthotopic neobladder after radical cystectomy for invasive bladder cancer. , 2008, Urology.

[114]  Sam S. Chang,et al.  Dilemmas in the treatment of urothelial cancers of the prostate. , 2009, Urologic oncology.

[115]  D. Penson,et al.  Urinary functional outcome following radical cystoprostatectomy and ileal neobladder reconstruction in male patients. , 2013, The Journal of urology.

[116]  Joon-ha Ok,et al.  Medical and surgical palliative care of patients with urological malignancies. , 2005, The Journal of urology.

[117]  A. Lembo,et al.  Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. , 2000, The Journal of urology.

[118]  F. Burkhard,et al.  Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[119]  A. Vickers,et al.  Standardization of pelvic lymphadenectomy performed at radical cystectomy , 2006, Cancer.

[120]  J. Thüroff,et al.  Cancer‐specific survival after radical cystectomy and standardized extended lymphadenectomy for node‐positive bladder cancer: prediction by lymph node positivity and density , 2009, BJU international.

[121]  K. Steven,et al.  Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall. , 1998, The Journal of urology.

[122]  F. Freiha,et al.  A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. , 1996, Journal of Urology.

[123]  S. Culine,et al.  Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[124]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[125]  S. Altınova,et al.  Robot‐assisted nerve‐sparing radical cystectomy with bilateral extended pelvic lymph node dissection (PLND) and intracorporeal urinary diversion for bladder cancer: initial experience in 27 cases , 2012, BJU international.

[126]  C. Sternberg,et al.  Can patient selection for bladder preservation be based on response to chemotherapy? , 2003, Cancer.

[127]  B. Bochner,et al.  Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. , 2009, European urology.

[128]  F. Porpiglia,et al.  Open versus laparoscopy-assisted radical cystectomy: results of a prospective study. , 2007, Journal of endourology.

[129]  M. Milowsky,et al.  Radical cystectomy in octogenarians--does morbidity outweigh the potential survival benefits? , 2009, The Journal of urology.

[130]  R. Coleman.  Metastatic bone disease: clinical features, pathophysiology and treatment strategies. , 2001, Cancer treatment reviews.

[131]  J. Gabrilove,et al.  Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the Urothelium , 1989 .

[132]  A. Zietman,et al.  Bladder preservation by combined modality therapy for invasive bladder cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[133]  P. Bassi,et al.  Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. , 1999, The Journal of urology.

[134]  N. Geller,et al.  M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. , 1988, The Journal of urology.

[135]  D. Margel,et al.  Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy. , 2007, Urology.

[136]  N. James,et al.  A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer , 2004, British Journal of Cancer.

[137]  S. Pahernik,et al.  Continent cutaneous urinary diversion: long-term follow-up of more than 800 patients with ileocecal reservoirs , 2006, World Journal of Urology.

[138]  P. Alken,et al.  Radical cystectomy--often too late? , 1987, European urology.

[139]  S. Groshen,et al.  The management of urethral transitional cell carcinoma after radical cystectomy for invasive bladder cancer. , 2004, The Journal of urology.

[140]  C. Dinney,et al.  Prostatic urethral biopsy has limited usefulness in counseling patients regarding final urethral margin status during orthotopic neobladder reconstruction. , 2008, The Journal of urology.

[141]  I. Tannock,et al.  Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[142]  T. Tanvetyanon.  Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors , 2005, Cancer.

[143]  X. Gamé,et al.  Radical Cystectomy in Patients Older than 75 Years: Assessment of Morbidity and Mortality , 2001, European Urology.

[144]  N. Vogelzang,et al.  Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer. , 2013, The Journal of urology.

[145]  T. Cheung,et al.  Comparison of dynamic helical CT and dynamic MR imaging in the evaluation of pelvic lymph nodes in cervical carcinoma. , 2000, AJR. American journal of roentgenology.

[146]  J. Bacik,et al.  Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[147]  J. Stein.  Contemporary concepts of radical cystectomy and the treatment of bladder cancer. , 2003, The Journal of urology.

[148]  John T. Wei,et al.  Development and validation of the Bladder Cancer Index: a comprehensive, disease specific measure of health related quality of life in patients with localized bladder cancer. , 2010, The Journal of urology.

[149]  A. Zietman,et al.  Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. , 2009, Urology.

[150]  W. Mcdougal,et al.  Acid-base and electrolyte disorders after urinary diversion , 2004, World Journal of Urology.

[151]  M. Babjuk,et al.  Guidelines on Urothelial Carcinomas of the Upper Urinary Tract , 2013 .

[152]  G. Hortobagyi,et al.  Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[153]  A. Hemal,et al.  Comparison of laparoscopic and open radical cystoprostatectomy for localized bladder cancer with 3-year oncological followup: a single surgeon experience. , 2007, The Journal of urology.

[154]  N. Zeybek,et al.  Comparison of Ileal Conduit and Transureteroureterostomy with Ureterocutaneostomy Urinary Diversion , 2006, Urologia Internationalis.

[155]  R. Cote,et al.  Indications for lower urinary tract reconstruction in women after cystectomy for bladder cancer: a pathological review of female cystectomy specimens. , 1995, The Journal of urology.

[156]  Peter Boyle,et al.  Tobacco smoking and cancer: A meta‐analysis , 2008, International journal of cancer.

[157]  C. Sternberg,et al.  Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results. , 1995, The Journal of urology.

[158]  H. Zincke,et al.  Carcinoma in Situ of the Bladder , 1980, Cancer.

[159]  A. Feinstein,et al.  The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. , 1974, Journal of chronic diseases.

[160]  E. Wallen,et al.  Fast track program in patients undergoing radical cystectomy: results in 362 consecutive patients. , 2010, Journal of the American College of Surgeons.

[161]  H. Rübben,et al.  Impact of surgical resection of bladder cancer metastases refractory to systemic therapy on performance score: a phase II trial. , 2001, Urology.

[162]  S. Fosså,et al.  Quality of life in patients with muscle-infiltrating bladder cancer and hormone-resistant prostatic cancer. , 1989, European urology.

[163]  Cary Siegel,et al.  Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[164]  W. Oh,et al.  Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[165]  Joaquim Bellmunt,et al.  Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. , 2012, European journal of cancer.

[166]  L. Bouter,et al.  How to measure comorbidity. a critical review of available methods. , 2003, Journal of clinical epidemiology.

[167]  L. Kiemeney,et al.  Discrepancy between clinical staging through bimanual palpation and pathological staging after cystectomy. , 2012, Urologic oncology.

[168]  G. Muto,et al.  Stage‐specific impact of extended versus standard pelvic lymph node dissection in radical cystectomy , 2013, International journal of urology : official journal of the Japanese Urological Association.

[169]  J. Witjes,et al.  An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. , 2009, European urology.

[170]  L. Balducci,et al.  General guidelines for the management of older patients with cancer. , 2000, Oncology.

[171]  J. Witjes,et al.  Follow-up of patients after curative bladder cancer treatment: guidelines vs. practice , 2010, Current opinion in urology.

[172]  S. Kropf,et al.  Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. , 2004, The Journal of urology.

[173]  P. Albers,et al.  Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). , 2009, European urology.

[174]  Sebastien Crouzet,et al.  Laparoscopic and robotic assisted radical cystectomy for bladder cancer: a critical analysis. , 2008, European urology.

[175]  D. Kroepfl,et al.  Radical cystectomy in patients aged ≥ 75 years: an updated review of patients treated with curative and palliative intent , 2005, BJU international.

[176]  S. Hutchings,et al.  Occupation and cancer in Britain , 2010, British Journal of Cancer.

[177]  P. Hoskin,et al.  Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[178]  S. Santa Cruz,et al.  Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[179]  Jörg Schmidbauer,et al.  Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. , 2004, The Journal of urology.

[180]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[181]  B. Ljungberg,et al.  Downstaging and survival benefits of neoadjuvant radiotherapy before cystectomy for patients with invasive bladder carcinoma , 2009, Scandinavian journal of urology and nephrology.

[182]  H. Moch,et al.  Patterns of Metastasis in Muscle-Invasive Bladder Cancer (pT2–4): An Autopsy Study on 367 Patients , 1999, Urologia Internationalis.

[183]  Alberto Redaelli,et al.  Bladder cancer: epidemiology, diagnosis, and management. , 2002, Cancer practice.

[184]  C. Sternberg,et al.  Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma , 2009, Cancer.

[185]  M. Kuczyk,et al.  Radical cystectomy with orthotopic neobladder for invasive bladder cancer: a critical analysis of long term oncological, functional and quality of life results. , 2010, International braz j urol : official journal of the Brazilian Society of Urology.

[186]  M. D. De Santis,et al.  New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder , 2007, Current opinion in urology.

[187]  W. Huang,et al.  An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. , 2003, The Journal of urology.

[188]  J. Stein,et al.  Indications and technique of the orthotopic neobladder in women. , 2002, The Urologic clinics of North America.

[189]  J. Wright,et al.  The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy , 2008, Cancer.

[190]  E. Olcott,et al.  Split-bolus MDCT urography with synchronous nephrographic and excretory phase enhancement. , 2007, AJR. American journal of roentgenology.

[191]  B. Norlén,et al.  5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. , 1999, The Journal of urology.

[192]  N. Wiklund,et al.  Recent advances in robot-assisted radical cystectomy , 2011, Current opinion in urology.

[193]  J. Carles,et al.  Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract , 2003, Cancer.

[194]  H. Ozen,et al.  The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. , 2006, The Journal of urology.

[195]  K. Jensen,et al.  Lymph node mapping in patients with bladder cancer undergoing radical cystectomy and lymph node dissection to the level of the inferior mesenteric artery , 2009, BJU international.

[196]  R. Wahlqvist,et al.  Five-year Followup of a Prospective Trial of Radical Cystectomy and Neoadjuvant Chemotherapy: Nordic Cystectomy Trial 1 , 1996 .

[197]  G. Bartsch,et al.  The risk of urethral tumors in female bladder cancer: can the urethra be used for orthotopic reconstruction of the lower urinary tract? , 1995, The Journal of urology.

[198]  A. Zietman,et al.  Organ-conserving approaches to muscle-invasive bladder cancer: future alternatives to radical cystectomy , 2000, Annals of medicine.

[199]  J. Montie,et al.  Performance status is a predictor of overall survival of elderly patients with muscle invasive bladder cancer. , 2006, The Journal of urology.

[200]  A. Papatsoris,et al.  Urinary diversion in high-risk elderly patients: modified cutaneous ureterostomy or ileal conduit? , 2005, Urology.

[201]  P. Russo,et al.  Cystectomy for bladder cancer: a contemporary series. , 2001, The Journal of urology.

[202]  S. Almenar,et al.  The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. , 2000, The Journal of urology.

[203]  P. Russo,et al.  Orthotopic urinary diversion after cystectomy for bladder cancer: implications for cancer control and patterns of disease recurrence. , 2003, The Journal of urology.

[204]  C. Bulpitt,et al.  Population-based multidimensional assessment of older people in UK general practice: a cluster-randomised factorial trial , 2004, The Lancet.

[205]  William A See,et al.  Multidetector computerized tomography urography as the primary imaging modality for detecting urinary tract neoplasms in patients with asymptomatic hematuria. , 2008, The Journal of urology.

[206]  I. Khubchandani,et al.  Neoplasia after ureterosigmoidostomy , 1999, Diseases of the colon and rectum.

[207]  V. Reuter,et al.  Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. , 1988, The Journal of urology.

[208]  J. Brismar,et al.  Bone Scintigraphy in Staging of Bladder Carcinoma , 1988, Acta radiologica.

[209]  D. Wood,et al.  Body image and bladder cancer specific quality of life in patients with ileal conduit and neobladder urinary diversions. , 2010, Urology.

[210]  N. Ikeda,et al.  Is there a role for pulmonary metastasectomy with a curative intent in patients with metastatic urinary transitional cell carcinoma? , 2011, The Annals of thoracic surgery.

[211]  Dieter Jocham,et al.  Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer--a multicenter study. , 2003, The Journal of urology.

[212]  Yair Lotan,et al.  Nomograms Provide Improved Accuracy for Predicting Survival after Radical Cystectomy , 2006, Clinical Cancer Research.

[213]  S. Daneshmand,et al.  Lymph node dissection technique is more important than lymph node count in identifying nodal metastases in radical cystectomy patients: a comparative mapping study. , 2011, European urology.

[214]  R. Mak,et al.  Bladder preservation: optimizing radiotherapy and integrated treatment strategies , 2008, BJU international.

[215]  G. Bartsch,et al.  Incidence of urethral tumor involvement in 910 men with bladder cancer , 2004, World Journal of Urology.

[216]  Jianping Zhang,et al.  Is whole-body fluorine-18 fluorodeoxyglucose PET/CT plus additional pelvic images (oral hydration–voiding–refilling) useful for detecting recurrent bladder cancer? , 2012, Annals of Nuclear Medicine.

[217]  B. Redman,et al.  Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[218]  T. Ratliff.  Urine markers for bladder cancer surveillance: a systematic review. , 2005, The Journal of urology.

[219]  J. Stein,et al.  The orthotopic T pouch ileal neobladder: experience with 209 patients. , 2004, The Journal of urology.

[220]  A. Maes,et al.  FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. , 2010, European urology.

[221]  U. Studer,et al.  A new multimodality technique accurately maps the primary lymphatic landing sites of the bladder. , 2010, European urology.

[222]  J. Stein,et al.  Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup. , 2007, The Journal of urology.

[223]  H. Herr,et al.  The value of a second transurethral resection in evaluating patients with bladder tumors. , 2000, The Journal of urology.

[224]  T. Kälble,et al.  Tumor induction and prophylaxis following different forms of intestinal urinary diversion in a rat model , 2004, Urological Research.

[225]  L. Sharples,et al.  Performance status score: do patients and their oncologists agree? , 2003, British Journal of Cancer.

[226]  E. Wallen,et al.  Robotic radical cystectomy for bladder cancer: surgical and pathological outcomes in 100 consecutive cases. , 2010, The Journal of urology.

[227]  D. Tulsky,et al.  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[228]  S. Groshen,et al.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[229]  M. Thun,et al.  Tobacco smoke and involuntary smoking. , 2004, IARC monographs on the evaluation of carcinogenic risks to humans.

[230]  I. Näslund,et al.  Hyperfractionated radiotherapy of bladder cancer. A ten-year follow-up of a randomized clinical trial. , 1994, Acta oncologica.

[231]  A. Pollack,et al.  Radiotherapy for stage T3b transitional cell carcinoma of the bladder. , 1996, Seminars in urologic oncology.

[232]  G. Raj,et al.  Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[233]  J. Debatin,et al.  Whole-body MR imaging: evaluation of patients for metastases. , 2004, Radiology.

[234]  G. Scagliotti,et al.  Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[235]  Peter A. Jones,et al.  Molecular targets and targeted therapies in bladder cancer management , 2008, World Journal of Urology.

[236]  H. Herr,et al.  Conservative management of muscle-infiltrating bladder cancer: prospective experience. , 1987, The Journal of urology.

[237]  A. Vickers,et al.  Impact of renal impairment on eligibility for adjuvant cisplatin‐based chemotherapy in patients with urothelial carcinoma of the bladder , 2006, Cancer.

[238]  A L Baert,et al.  Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: prospective study of 285 patients. , 1994, Radiology.

[239]  M. Gerken,et al.  Is there evidence for a multidisciplinary follow-up after urological cancer? An evaluation of subsequent cancers , 2008, World Journal of Urology.

[240]  N. Shakhssalim,et al.  Palliative treatment of intractable hematuria in context of advanced bladder cancer: a systematic review. , 2009, Urology journal.

[241]  W. Meinhardt,et al.  Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[242]  S. Phillips,et al.  Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy. , 2011, The Journal of urology.

[243]  R. Sylvester,et al.  Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[244]  F. Montorsi,et al.  Stage‐specific impact of pelvic lymph node dissection on survival in patients with non‐metastatic bladder cancer treated with radical cystectomy , 2012, BJU international.

[245]  U. Ha,et al.  Laparoscopic versus open radical cystectomy for the management of bladder cancer: Mid‐term oncological outcome , 2010, International journal of urology : official journal of the Japanese Urological Association.

[246]  H. Scher,et al.  Surgery of invasive bladder cancer: is pathologic staging necessary? , 1990, Seminars in oncology.

[247]  R. Fimmers,et al.  Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[248]  M. Zaghloul.  The need to revisit adjuvant and neoadjuvant radiotherapy in bladder cancer , 2010, Expert review of anticancer therapy.

[249]  S. Donat.  Staged based directed surveillance of invasive bladder cancer following radical cystectomy: valuable and effective? , 2006, World Journal of Urology.

[250]  C. Siegel.  Bladder cancer: analysis of multi-detector row helical CT enhancement pattern and accuracy in tumor detection and perivesical staging. , 2005, The Journal of urology.

[251]  L. Collette,et al.  Morbidity from pelvic lymphadenectomy in men undergoing radical prostatectomy. , 2006, European urology.

[252]  J. B. Jensen,et al.  Extended versus limited lymph node dissection in radical cystectomy: Impact on recurrence pattern and survival , 2012, International journal of urology : official journal of the Japanese Urological Association.

[253]  C. Rödel,et al.  Trimodality treatment and selective organ preservation for bladder cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[254]  R. Autorino,et al.  Health related quality of life after radical cystectomy: comparison of ileal conduit to continent orthotopic neobladder. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[255]  J. Huguet.  Follow-up after radical cystectomy based on patterns of tumor recurrence and its risk factors , 2013 .

[256]  S. Nilsson,et al.  Positron emission tomography with L-methyl-11C-methionine in the monitoring of therapy response in muscle-invasive transitional cell carcinoma of the urinary bladder. , 1994, British journal of urology.

[257]  J. Dunn,et al.  Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. , 1991, British journal of urology.

[258]  J. Muscat,et al.  Planned preoperative radiation therapy in muscle invasive bladder cancer; results of a meta-analysis. , 1998, Anticancer research.

[259]  J. Montie.  Intravesical bacille calmette-guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. , 2005, The Journal of urology.

[260]  R. Sylvester,et al.  Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[261]  J. Ware,et al.  Evaluating Translations of Health Status Questionnaires: Methods From the IQOLA Project , 1995, International Journal of Technology Assessment in Health Care.

[262]  P. Schellhammer,et al.  Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra. , 2007, Clinical genitourinary cancer.

[263]  B. Guillonneau,et al.  Cystectomy with prostate sparing for bladder cancer in 100 patients: 10-year experience. , 2002, The Journal of urology.

[264]  L. Kiemeney,et al.  The present and future burden of urinary bladder cancer in the world , 2009, World Journal of Urology.

[265]  Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. , 1994, IARC monographs on the evaluation of carcinogenic risks to humans.

[266]  R. Hautmann,et al.  ICUD-EAU International Consultation on Bladder Cancer 2012: Urinary diversion. , 2013, European urology.

[267]  F. Burkhard,et al.  Treatment of urethral recurrence following radical cystectomy and ileal bladder substitution. , 2004, The Journal of urology.

[268]  M. Mazumdar,et al.  Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[269]  Y. Lotan,et al.  Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. , 2010, The Journal of urology.

[270]  J. Morley,et al.  Controlled Trial of a Geriatric Case‐Finding and Liaison Service in an Emergency Department , 1996, Journal of the American Geriatrics Society.

[271]  H. Scher,et al.  Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[272]  S. Almenar,et al.  The optimum timing of radical cystectomy for patients with recurrent high‐risk superficial bladder tumour , 2004, BJU international.

[273]  A. Pycha,et al.  Four years experience in bladder preserving management for muscle invasive bladder cancer. , 2005, European urology.

[274]  S. Groshen,et al.  Urethral recurrence in patients with orthotopic ileal neobladders. , 1996, The Journal of urology.

[275]  S. Shariat,et al.  Stage specific lymph node metastasis mapping in radical cystectomy specimens. , 2004, The Journal of urology.

[276]  M. Ghoneim,et al.  Functional results of orthotopic ileal neobladder with serous-lined extramural ureteral reimplantation: experience with 450 patients. , 2001, The Journal of urology.

[277]  Y. Lotan,et al.  Management of elderly patients with urothelial carcinoma of the bladder: guideline concordance and predictors of overall survival , 2010, BJU international.

[278]  C. Lawton.  Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer , 2009 .

[279]  B. Gross,et al.  Upper abdominal lymph nodes: criteria for normal size determined with CT. , 1991, Radiology.

[280]  D. Johnson,et al.  Long-term results following thoracotomy for metastatic bladder cancer. , 1982, Urology.

[281]  Eiji Kikuchi,et al.  Comparison of CT urography and excretory urography in the detection and localization of urothelial carcinoma of the upper urinary tract. , 2011, AJR. American journal of roentgenology.

[282]  Yusuke Nakamura,et al.  Validation study of the prediction system for clinical response of M‐VAC neoadjuvant chemotherapy , 2007, Cancer science.

[283]  Vikas Kundra,et al.  Imaging in oncology from the University of Texas M. D. Anderson Cancer Center: diagnosis, staging, and surveillance of prostate cancer. , 2007, AJR. American journal of roentgenology.

[284]  F. Freiha,et al.  Cisplatin, methotrexate and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urothelium. , 1993, The Journal of urology.

[285]  R. Fisher,et al.  Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder. , 1995, International journal of radiation oncology, biology, physics.

[286]  W. Otto,et al.  Comorbidity and performance indices as predictors of cancer-independent mortality but not of cancer-specific mortality after radical cystectomy for urothelial carcinoma of the bladder. , 2012, European urology.

[287]  M. Melekos,et al.  Ten Years’ Experience with the Submucosally Embedded in situ Appendix in Continent Cutaneous Diversion , 2001, European Urology.

[288]  F. Montorsi,et al.  Development and Validation of a Reference Table for Prediction of Postoperative Mortality Rate in Patients Treated with Radical Cystectomy: A Population-based Study , 2011, Annals of Surgical Oncology.

[289]  R. Svatek,et al.  Role and Extent of Lymphadenectomy During Radical Cystectomy for Invasive Bladder Cancer , 2012, Current Urology Reports.

[290]  B. Linn,et al.  CUMULATIVE ILLNESS RATING SCALE , 1968, Journal of the American Geriatrics Society.

[291]  G. Sonpavde,et al.  A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. , 2011, The Lancet. Oncology.

[292]  S. Holmäng,et al.  Long-term followup of all patients with muscle invasive (stages T2, T3 and T4) bladder carcinoma in a geographical region. , 1997, The Journal of urology.

[293]  S. Groshen,et al.  Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[294]  J. Montie,et al.  Follow-up strategies and management of recurrence in urologic oncology bladder cancer: invasive bladder cancer. , 2003, The Urologic clinics of North America.

[295]  L. Lawler.  MR imaging of the bladder. , 2003, Radiologic clinics of North America.

[296]  A. Pycha,et al.  Does extended lymphadenectomy increase the morbidity of radical cystectomy? , 2004, BJU international.

[297]  J. Huguet,et al.  Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. , 2005, European urology.

[298]  N. Cowan.  CT urography for hematuria , 2012, Nature Reviews Urology.

[299]  Yusuke Nakamura,et al.  Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[300]  Does Radical Cystectomy Improve Overall Survival in Octogenarians with Muscle-Invasive Bladder Cancer? , 2011, Korean journal of urology.

[301]  Gerhard Jakse,et al.  A second-look TUR in T1 transitional cell carcinoma: why? , 2004, European urology.

[302]  Y. Lotan,et al.  A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome , 2007, BJU international.

[303]  S. Fosså,et al.  Clinical significance of the "palpable mass" in patients with muscle-infiltrating bladder cancer undergoing cystectomy after pre-operative radiotherapy. , 1991, British journal of urology.

[304]  F. Burkhard,et al.  Long-term outcome of ileal conduit diversion. , 2003, The Journal of urology.

[305]  R. Hautmann,et al.  25 years of experience with 1,000 neobladders: long-term complications. , 2011, The Journal of urology.

[306]  I. Tannock,et al.  Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. , 2007, Urologic oncology.

[307]  Z. Piao,et al.  Solitary cerebral metastasis from transitional cell carcinoma after a 14-year remission of urinary bladder cancer treated with gemcitabine: Case report and literature review , 2012, Surgical neurology international.

[308]  E. Lindholm,et al.  Long–Time Experience with the Kock Ileal Reservoir for Continent Urinary Diversion , 2001, European Urology.

[309]  R. Hautmann,et al.  Long-term results of standard procedures in urology: the ileal neobladder , 2006, World Journal of Urology.

[310]  N. Cowan,et al.  Multidetector computed tomography urography for diagnosing upper urinary tract urothelial tumour , 2007, BJU international.

[311]  P. Dahm,et al.  Disease specific survival as endpoint of outcome for bladder cancer patients following radical cystectomy. , 2002, European urology.

[312]  S. Groshen,et al.  Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction , 1995, Cancer.

[313]  I. Tannock,et al.  A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[314]  F. Wiklund,et al.  Results of second-look resection after primary resection of T1 tumour of the urinary bladder , 2005, Scandinavian journal of urology and nephrology.

[315]  R. Fimmers,et al.  Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology trial AB20/99). , 2011, European urology.

[316]  U. Studer,et al.  Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[317]  P. Tanis,et al.  Surgery for isolated lung metastasis in two patients with bladder cancer. , 2005, Urology.

[318]  R. Kuefer,et al.  Oncological followup after radical cystectomy for bladder cancer-is there any benefit? , 2009, The Journal of urology.

[319]  E. Tuzel,et al.  Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder. , 2005, European urology.

[320]  M. Lucia,et al.  Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma. , 2011, Urology.

[321]  M. Higashiyama,et al.  Outcome of surgical resection of pulmonary metastasis from urinary tract transitional cell carcinoma. , 2010, Interactive cardiovascular and thoracic surgery.

[322]  A. Vickers,et al.  Age‐adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer , 2008, Cancer.

[323]  A R Feinstein,et al.  THE PRE-THERAPEUTIC CLASSIFICATION OF CO-MORBIDITY IN CHRONIC DISEASE. , 1970, Journal of chronic diseases.

[324]  J. Hainsworth,et al.  Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[325]  R. Bahnson,et al.  EFFICACY AND SAFETY OF VALRUBICIN FOR THE TREATMENT OF BACILLUS CALMETTE-GUERIN REFRACTORY CARCINOMA IN SITU OF THE BLADDER , 2000 .

[326]  P. Boström,et al.  Risk factors for mortality and morbidity related to radical cystectomy , 2009, BJU international.

[327]  George Gayagay,et al.  Validation of the Cumulative Illness Rating Scale (CIRS) in hospitalized nonagenarians. , 2007, Archives of gerontology and geriatrics.

[328]  C. Tangen,et al.  Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. , 2009, Urologic oncology.

[329]  P. Carroll,et al.  Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. , 2007, The Journal of urology.

[330]  M. Stöckle,et al.  MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. , 2010, Neoplasia.

[331]  L. Seymour,et al.  Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. , 2002, Urologic oncology.

[332]  D. Penson,et al.  Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. , 2005, The Journal of urology.

[333]  H. Loertzer,et al.  Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. , 2000, The Journal of urology.

[334]  J. Portillo,et al.  Original Articles: Bladder Cancer: Neoadjuvant Cisplatin Chemotherapy Before Radical Cystectomy in Invasive Transitional Cell Carcinoma of the Bladder: A Prospective Randomized Phase III Study , 1995 .

[335]  E. Solsona,et al.  Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer. , 2010, The Journal of urology.

[336]  Yair Lotan,et al.  Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. , 2006, The Journal of urology.

[337]  Matthias Egger,et al.  Home visits to prevent nursing home admission and functional decline in elderly people: systematic review and meta-regression analysis. , 2002, JAMA.

[338]  E. Ioachim,et al.  Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components , 2006, BMC Cancer.

[339]  D. Penson,et al.  Clinical outcomes and recurrence predictors of lymph node positive urothelial cancer after cystectomy. , 2009, The Journal of urology.

[340]  V. Ficarra,et al.  Complications and mortality after radical cystectomy for bladder transitional cell cancer. , 2009, The Journal of urology.

[341]  M. Ghoneim,et al.  Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. , 2008, The Journal of urology.

[342]  H. Grossman,et al.  A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. , 2007, The Journal of urology.

[343]  C. Sternberg,et al.  Chemotherapy with an every‐2‐week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin‐based therapy , 2001, Cancer.

[344]  G. Bartsch,et al.  Original Articles: Bladder Cancer: The Risk of Urethral Tumors in Female Bladder Cancer: Can the Urethra be Used for Orthotopic Reconstruction of the Lower Urinary Tract? , 1995 .

[345]  W. Whitmore,et al.  Radical cystectomy with or without prior irradiation in the treatment of bladder cancer. , 1977, Transactions of the American Association of Genito-Urinary Surgeons.

[346]  W. Mcdougal.  The continent urinary diversion. , 1987, The Journal of urology.

[347]  P. Franzone,et al.  Alternating chemo-radiotherapy in bladder cancer: a conservative approach. , 1995, International journal of radiation oncology, biology, physics.

[348]  D. Lamm,et al.  Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. , 2000, The Journal of urology.

[349]  G. Muto,et al.  Complications following radical cystectomy for bladder cancer in the elderly. , 2009, European urology.

[350]  M. Grimm,et al.  Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. , 2003, The Journal of urology.

[351]  M. Mencoboni,et al.  Single-Agent Gemcitabine in Previously Untreated Elderly Patients with Advanced Bladder Carcinoma: Response to Treatment and Correlation with the Comprehensive Geriatric , 2004, Oncology.

[352]  Stefano Galli,et al.  A cost comparison of laparoscopic versus open radical cystoprostatectomy and orthotopic ileal neobladder at a single institution. , 2007, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.

[353]  L. Collette,et al.  Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[354]  H. von der Maase,et al.  Long-term survival after gemcitabine and cisplatin in patients with locally advanced transitional cell carcinoma of the bladder: focus on supplementary treatment strategies. , 2007, European urology.

[355]  J. Carles,et al.  Feasibilty study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function , 2006 .

[356]  R. Hautmann,et al.  Lessons learned from 1,000 neobladders: the 90-day complication rate. , 2010, The Journal of urology.

[357]  A Rajesh,et al.  Bladder cancer: evaluation of staging accuracy using dynamic MRI. , 2011, Clinical radiology.

[358]  R. Hautmann,et al.  A critical analysis of orthotopic bladder substitutes in adult patients with bladder cancer: is there a perfect solution? , 2010, European urology.

[359]  K. Golka,et al.  N-Acetyltransferase-2 and Medical History in Bladder Cancer Cases with a Suspected Occupational Disease (BK 1301) in Germany , 2008, Journal of toxicology and environmental health. Part A.

[360]  R. Millikan,et al.  Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? , 2003, The Journal of urology.

[361]  M. Babjuk,et al.  Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. , 2012, European urology.

[362]  M. Krzakowski,et al.  Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors , 2004, Cancer.

[363]  R. Autorino,et al.  Clinicopathologic features of prostate adenocarcinoma incidentally discovered at the time of radical cystectomy: an evidence-based analysis. , 2007, European urology.

[364]  H. Habermann,et al.  Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? , 2002, Urology.

[365]  S. Groshen,et al.  Adjuvant chemotherapy following cystectomy benefits patients with deeply invasive bladder cancer. , 1990, Seminars in urology.

[366]  Ashesh B Jani,et al.  An electronic application for rapidly calculating Charlson comorbidity score , 2004, BMC Cancer.

[367]  N Karssemeijer,et al.  Staging urinary bladder cancer after transurethral biopsy: value of fast dynamic contrast-enhanced MR imaging. , 1996, Radiology.

[368]  H. G. van der Poel,et al.  Urinary diversions after cystectomy: the association of clinical factors, complications and functional results of four different diversions. , 2008, European urology.

[369]  M. Stöckle,et al.  Complete long‐term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer , 2006, BJU international.

[370]  L. Carmignani,et al.  Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients. , 2012, The Journal of urology.

[371]  J. Witjes,et al.  Primary staging of urinary bladder carcinoma: the role of MRI and a comparison with CT , 2004, European Radiology.

[372]  John T. Wei,et al.  The impact of co-morbid disease on cancer control and survival following radical cystectomy. , 2003, The Journal of urology.

[373]  T. Lebret,et al.  Urethral Recurrence of Transitional Cell Carcinoma of the Bladder , 1998, European Urology.

[374]  C. Hodges,et al.  Radical cystectomy for bladder cancer. , 1978, The Journal of urology.

[375]  J. Paradelo,et al.  Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone: a phase III intergroup study. , 1997, The Journal of urology.

[376]  M. Extermann,et al.  Management of cancer in the older person: a practical approach. , 2000, The oncologist.

[377]  D. Roychowdhury,et al.  Health-related quality-of-life parameters as independent prognostic factors in advanced or metastatic bladder cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[378]  J. Dunst,et al.  Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[379]  J. Eastham.  Do high-volume hospitals and surgeons provide better care in urologic oncology? , 2009, Urologic oncology.

[380]  J. Birkmeyer,et al.  Trends in hospital volume and operative mortality for high-risk surgery. , 2011, The New England journal of medicine.

[381]  P. Carroll,et al.  Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. , 1994, Radiology.

[382]  E. Klein,et al.  Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. , 2008, Journal of Urology.

[383]  Franz Quehenberger,et al.  Multiphasic multidetector-row CT (MDCT) in detection and staging of transitional cell carcinomas of the upper urinary tract , 2006, European Radiology.

[384]  Sam S. Chang,et al.  Volume outcomes of cystectomy--is it the surgeon or the setting? , 2012, The Journal of urology.

[385]  D. Lamm,et al.  Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. , 2002, The Journal of urology.

[386]  P. Dasgupta,et al.  The role of laparoscopic and robotic cystectomy in the management of muscle-invasive bladder cancer with special emphasis on cancer control and complications. , 2011, European urology.

[387]  J. Stockman,et al.  Association Between Smoking and Risk of Bladder Cancer Among Men and Women , 2013 .

[388]  M. Schwaiger,et al.  Diagnostic efficacy of [11C]choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy. , 2012, European urology.

[389]  Andreas Böhle,et al.  Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1 and CIS) , 2014 .

[390]  J. Carles,et al.  Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function. , 2012, European journal of cancer.

[391]  J. Huguet,et al.  Management of urethral recurrence in patients with Studer ileal neobladder. , 2003, European urology.

[392]  S. Groshen,et al.  Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients. , 1999, The Journal of urology.

[393]  J. Bellmunt,et al.  New therapeutic challenges in advanced bladder cancer. , 2012, Seminars in oncology.

[394]  P. Sogani,et al.  Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? , 2001, The Journal of urology.

[395]  A. Goel,et al.  Re: Jason A. Efstathiou, Daphna Y. Spiegel, William U. Shipley, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 2012;61:705-11. , 2012, European urology.

[396]  U. Nagele,et al.  Cystectomy – Technical Considerations in Male and Female Patients , 2005 .

[397]  P. Lavori,et al.  A controlled trial of inpatient and outpatient geriatric evaluation and management. , 2002, The New England journal of medicine.

[398]  Å. Månsson,et al.  The quality of life in men after radical cystectomy with a continent cutaneous diversion or orthotopic bladder substitution: is there a difference? , 2002, BJU international.

[399]  P. Albers,et al.  Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[400]  M. R. W. Engelbrecht,et al.  MR imaging of the male pelvis , 1999, European Radiology.

[401]  J. Gore,et al.  Mortality increases when radical cystectomy is delayed more than 12 weeks , 2009, Cancer.

[402]  R. Sylvester,et al.  Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[403]  H. Thomsen,et al.  Nephrogenic systemic fibrosis: history and epidemiology. , 2009, Radiologic clinics of North America.

[404]  Pierre I Karakiewicz,et al.  A population‐based competing‐risks analysis of the survival of patients treated with radical cystectomy for bladder cancer , 2011, Cancer.

[405]  G. Dalbagni,et al.  Value of urethral wash cytology in the retained male urethra after radical cystoprostatectomy. , 2003, The Journal of urology.

[406]  S Majewski,et al.  Dose fractionation and tumour repopulation in radiotherapy for bladder cancer. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[407]  M. Benson,et al.  Muscle-invasive urothelial carcinoma of the bladder. , 2007, Urology.

[408]  G. Muto,et al.  Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[409]  T. Ahlering,et al.  Laparoscopic assisted radical cystectomy with ileal neobladder: a comparison with the open approach. , 2004, The Journal of urology.

[410]  Y. Lotan,et al.  Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy , 2013, BJU international.

[411]  J. Stein,et al.  Complications of radical cystectomy. , 2007, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.

[412]  R. Hautmann,et al.  Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. , 2012, European urology.

[413]  Michael Cookson,et al.  Health related quality of life assessment after radical cystectomy: comparison of ileal conduit with continent orthotopic neobladder. , 2002, The Journal of urology.

[414]  N. Clarke,et al.  Differential complication rates following radical cystectomy in the irradiated and nonirradiated pelvis. , 2010, European urology.

[415]  O. Hughes,et al.  Safety and feasibility of laparoscopic radical cystectomy for the treatment of bladder cancer. , 2013, Journal of endourology.

[416]  P. Clark.  Radical cystectomy for carcinoma of the bladder. , 1978, British journal of urology.

[417]  J. Witjes,et al.  Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. , 1998, Radiology.

[418]  Y. Osman,et al.  Bladder cancer with obstructive uremia: oncologic outcome after definitive surgical management. , 2005, Urology.

[419]  Yair Lotan,et al.  Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. , 2006, The Journal of urology.

[420]  J. Witjes,et al.  Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer. , 2012, European urology.

[421]  D. Bajorin,et al.  Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. , 2001, The Journal of urology.

[422]  S. Culine,et al.  A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen , 2006, British Journal of Cancer.

[423]  D. Ackermann,et al.  Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guérin for carcinoma in situ of the bladder. , 1995, British journal of urology.

[424]  V. Paleri,et al.  Applicability of the adult comorbidity evaluation – 27 and the Charlson indexes to assess comorbidity by notes extraction in a cohort of United Kingdom patients with head and neck cancer: a retrospective study , 2002, The Journal of Laryngology & Otology.

[425]  A. Sagalowsky,et al.  Prevention and management of complications following radical cystectomy for bladder cancer. , 2010, European urology.

[426]  P. Albers,et al.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[427]  L. Mazzucchelli,et al.  Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. , 1994, The Journal of urology.

[428]  A. Böhle,et al.  Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. , 2004, Urology.

[429]  Sam S. Chang,et al.  Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. , 2003, The Journal of urology.

[430]  R. Millikan,et al.  Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. , 2004, The Journal of urology.

[431]  P. Vock,et al.  Is ileal orthotopic bladder substitution with an afferent tubular segment detrimental to the upper urinary tract in the long term? , 2002, The Journal of urology.

[432]  M. Dimopoulos,et al.  Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[433]  Çağatay Göğüş,et al.  The significance of random bladder biopsies in superficial bladder cancer , 2004, International Urology and Nephrology.

[434]  O. S. Nielsen,et al.  Neoadjuvant Chemotherapy with Cisplatin and Methotrexate in Patients with Muscle-Invasive Bladder Tumours , 2002, Acta oncologica.

[435]  H. von der Maase,et al.  Metastatic Urothelial Cancer: Evaluation of Prognostic Factors and Change in Prognosis during the Last Twenty Years , 2001, European Urology.

[436]  E. Skinner,et al.  Quality of life after cystectomy and urinary diversion: an evidence based analysis. , 2005, The Journal of urology.

[437]  Greenberg,et al.  Management of Cancer in the Older Aged Person. , 1994, Cancer Control: Journal of the Moffitt Cancer Cente.

[438]  D. Wood,et al.  Stomal complications of ileal conduits are significantly higher when formed in women with intractable urinary incontinence. , 2004, The Journal of urology.

[439]  T. Lebret,et al.  The Z‐shaped ileal neobladder after radical cystectomy: an 18 years experience with 329 patients , 2011, BJU international.

[440]  I. Näslund,et al.  Evaluation of clinical staging before cystectomy in transitional cell bladder carcinoma: a long-term follow-up of 276 consecutive patients. , 1998, British journal of urology.

[441]  C. Sternberg,et al.  Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin: 18-year experience. , 2002, Urology.

[442]  P. Albers,et al.  Randomised phase II trial of gemcitabine and paclitaxel second‐line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99) , 2005, International journal of clinical practice.

[443]  G. Jakse,et al.  Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early? , 2001, The Journal of urology.

[444]  G. Bartsch,et al.  Life after cystectomy and orthotopic neobladder versus ileal conduit urinary diversion. , 2001, Seminars in urologic oncology.

[445]  Sam S. Chang,et al.  Complications of radical cystectomy for nonmuscle invasive disease: comparison with muscle invasive disease. , 2003, The Journal of urology.

[446]  S Greenfield,et al.  The Importance of Co-existent Disease in the Occurrence of Postoperative Complications and One-Year Recovery in Patients Undergoing Total Hip Replacement: Comorbidity and Outcomes After Hip Replacement , 1993, Medical care.